Categories
Change Password!
Reset Password!
Bismuth administration improves the
elimination of H. pylori when used with tegoprazan and lansoprazole-based
therapy.
As per the findings of a retrospective study, the helicobacter pylori (H. pylori) elimination success rates of tegoprazan and lansoprazole-based first-line triple therapy regimen for seven days was found to exceed 82% with acceptable tolerability when given with bismuth in elimination-naive people. Investigators undertook this study for investigating the efficacy and safety of a proton pump inhibitor (PPI)-based first-line therapy with bismuth in comparison with potassium-competitive acid blocker (P-CAB)-based first-line elimination therapy with bismuth in elimination-naive H. pylori-infected people.
Prior to approval of the P-CAB-based elimination therapy, twice-daily administration of a regimen containing 30 mg lansoprazole, 1 g amoxicillin, 500 mg clarithromycin, and 300 mg bismuth potassium citrate was prescribed for seven days. Following approval, 30 mg lansoprazole was replaced with 50 mg tegoprazan. Examination of clarithromycin resistance was done in people who underwent gastroscopic biopsy. With the aid of the 13C-urea breath test, efficacy was assessed.
Of 381 eradication-naive subjects, the elimination rate of H. pylori in the tegoprazan group and lansoprazole group is shown in Table 1:
Clarithromycin resistance was noted
in 30 (20.1%) of the 148 people (74 from each arm), and only 4 of the 16
clarithromycin-resistant people in the tegoprazan arm attained successful H.
pylori elimination. No severe adverse effects were witnessed. For
elimination failure, poor patient compliance (odds ratio [OR] =17.1) and
clarithromycin resistance (OR= 42.1) were the independent risk factors.
Nevertheless, efficacy was found to
be limited in clarithromycin-resistant strains since neither 30 mg lansoprazole
nor 50 mg tegoprazan attained acceptable elimination rates when given twice
daily for seven days in clarithromycin-resistant people.
The Yonsei Medical Journal
Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth
Ji Yeon Kim et al.
Comments (0)